Molecular Mechanism of Ephedra Herba and Amygdalus Communis Vas Couplet Medicines in the Treatment of Bronchopneumonia Based on Network Pharmacology

Xue Meng; Yan Meixing; Zhang Tai; Qu Suxin

doi:10.13407/j.cnki.jpp.1672-108X.2022.05.001

您当前的位置：

首页 >

文章列表页 >

Molecular Mechanism of Ephedra Herba and Amygdalus Communis Vas Couplet Medicines in the Treatment of Bronchopneumonia Based on Network Pharmacology

更新时间：2022-06-10

- Molecular Mechanism of Ephedra Herba and Amygdalus Communis Vas Couplet Medicines in the Treatment of Bronchopneumonia Based on Network Pharmacology
- Vol. 28, Issue 5, Pages: 1-6(2022)
- 作者机构：
  
  山东省青岛市妇女儿童医院,山东,青岛,266000
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2022.05.001
  CLC：
- Published：2022，
扫描看全文
Xue Meng, Yan Meixing, Zhang Tai, et al. Molecular Mechanism of Ephedra Herba and Amygdalus Communis Vas Couplet Medicines in the Treatment of Bronchopneumonia Based on Network Pharmacology. [J]. 28(5):1-6(2022)
DOI：

Xue Meng, Yan Meixing, Zhang Tai, et al. Molecular Mechanism of Ephedra Herba and Amygdalus Communis Vas Couplet Medicines in the Treatment of Bronchopneumonia Based on Network Pharmacology. [J]. 28(5):1-6(2022) DOI： 10.13407/j.cnki.jpp.1672-108X.2022.05.001.

摘要

目的：基于网络药理学方法探讨麻黄-苦杏仁药对（Ephedra Herba and Amygdalus Communis Vas couplet medicines，EHACV）治疗支气管肺炎的作用机制。方法：基于中药系统药理学技术平台（TCMSP）获取麻黄-苦杏仁药对化学成分及其对应靶点，通过CTD、人类基因数据库（GeneCards）获取支气管肺炎相关靶点，将药物靶点与疾病靶点映射得到麻黄-苦杏仁药对作用于支气管肺炎的预测靶点。运用Cytoscape软件系统构建药对成分-疾病靶点网络和蛋白互作（PPI）网络，最后进行GO和KEGG富集分析。结果：从麻黄-苦杏仁药对中筛选出48个活性化合物，去重后得到145个药物靶点，与支气管肺炎疾病靶点取交集进行相映射，共得到108个共有作用靶点，如AKT1、MAPK3、JUN、VEGFA等，KEGG富集分析主要涉及白细胞介素（IL）-17信号通路、肿瘤坏死因子（TNF）信号通路、血管内皮生长因子（VEGF）信号通路等。结论：运用网络药理学方法预测了麻黄-苦杏仁药对治疗支气管肺炎可能的疾病靶点和生物过程，为分子机制的验证提供思路和依据。

Abstract

Objective: To probe into the mechanism of Ephedra Herba and Amygdalus Communis Vas couplet medicines (EHACV) in the treatment of bronchopneumonia based on network pharmacology. Methods: Based on the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP)

the chemical compositions of EHACV and correspondent targets were obtained. The targets of bronchopneumonia were obtained from the comparative toxicogenomics database (CTD) and GeneCards databases. Then the targets of chemical compositions were mapped to the targets of bronchopneumonia to predict the targets of EHACV acting on bronchopneumonia. The compositions-targets network and protein-protein interactions (PPI) network were established by using the Cytoscape software. Gene ontology enrichment and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis were performed based on DAVID database. Results: A total of 48 kinds of active compounds were screened out

and 145 drug targets were obtained after deduplication. And 108 common targets associated with bronchopneumonia were obtained

including AKT1

MAPK3

JUN and VEGFA. KEGG enrichment analysis mainly involved interleukin (IL)-17 signaling pathway

tumor necrosis factor (TNF) signaling pathway

vascular endothelial growth factor (VEGF) signaling pathway

etc. Conclusion: The network pharmacology method is used to predict the possible disease targets and biological processes of EHACV in the treatment of bronchopneumonia

which provides ideas and basis for the verification of the molecular mechanism.

关键词

麻黄苦杏仁药对网络药理学支气管肺炎

Keywords

Ephedra HerbaAmygdalus Communis Vascouplet medicinesnetwork pharmacologybronchopneumonia

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploration of Medication Rules and Core Mechanism of Traditional Chinese Medicine in the Treatment of Adenoidal Hypertrophy Based on Data Mining and Network Pharmacology

Mechanism of the Core Drugs of Changju Zhidong Prescription in the Treatment of Tic Disorders Based on

Rationality Analysis of Inhaled Medication for Pediatric Bronchopneumonia Based on Children Drug Utilization Index

Exploring the Active Components and Mechanism of Xiao’er Qingjie Fanggan Granule in the Preventionand Treatment of Influenza A

Mechanism of Schisandra Chinensis in the Treatment of Inflammatory Bowel Disease Based on Network Pharmacology

Related Author

Wang Junhong

Zhang Qiang

Yuan Zhenhua

Liu Miaomiao

Wang Junhong

Zhai Rui

Liu Yuan

Zhang Qiang

Related Institution

Dongzhimen Hospital, Beijing University of Chinese Medicine

Dongzhimen Hospital,Beijing University of Chinese Medicine, Beijing　100700, ChinaBeijing University of Chinese Medicine, Beijing

Shanghai Songjiang District Center Hospital, Shanghai

Shaanxi University of Chinese Medicine,Shaanxi Xianyang

Shaanxi Academy of Traditional Chinese Medicine, Xi’an

⁰